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Abstract 
Background 
Around 30% of individuals with schizophrenia remain symptomatic and markedly impaired 
despite standard antipsychotic treatment and are considered to be treatment-resistant. 
Clinicians are currently unable to predict which patients are at higher risk of treatment-
resistance. 
Aims 
To determine whether genetic liability for schizophrenia and/or clinical characteristics 
measurable at illness onset can prospectively indicate a higher risk of treatment-resistant 
psychosis (TRP). 
Method 
In 1070 individuals with schizophrenia or related psychotic disorders, schizophrenia polygenic 
risk scores (PRS) and large copy number variation (CNVs) were assessed for enrichment in TRP. 
Regression and machine-learning approaches were used to investigate the association of 
phenotypes related to demographics, family history, premorbid factors, and illness onset with 
TRP. 
Results 
A younger age of onset of psychosis (OR=0.94, p=7.79x10-13) and poor premorbid social 
adjustment (OR=1.64, p=2.41x10-4) increased the risk of TRP in univariate regression analyses. 
These factors remained associated in multivariate regression analyses, which also found lower 
premorbid IQ (OR=0.98, p=7.76x10-3), a younger father’s age at birth (OR=0.97, p=0.015), and 
cannabis use (OR=1.60, p=0.025) to increase the risk of TRP. Machine-learning approaches 
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found age at onset of psychosis to be the most important predictor and also identified 
premorbid IQ and poor premorbid social adjustment as predictors of TRP mirroring the findings 
from the regression analyses. Genetic liability for schizophrenia indicated by PRS and CNVs were 
not associated with TRP.  
Conclusions 
Patients with an earlier age of onset of psychosis and poor premorbid functioning are more 
likely to be treatment-resistant. The genetic architecture of susceptibility to schizophrenia may 
be distinct from that of treatment outcomes. 
 
Introduction 
Around 30% of individuals with schizophrenia will remain symptomatic and significantly 
impaired despite standard antipsychotic treatment and are considered to have treatment-
resistant schizophrenia1. Treatment-resistance is usually defined as a failure to respond to two 
antipsychotic trials of sufficient dose and duration and is one of the most disabling forms of 
illness, and thus presents a major clinical challenge2. It is as yet unclear whether treatment-
resistance is better conceptualised as a form of illness at the severe end of a spectrum, or as a 
more biologically homogeneous subgroup of those with schizophrenia, although recent 
evidence has supported the latter hypothesis3. Clozapine is the only medication with proven 
effectiveness for patients with treatment-resistant schizophrenia4. Nonetheless, substantial 
delays in receiving clozapine treatment are commonplace5, and these delays are associated with 
poorer outcomes6. Ensuring the right patients have timely access to clozapine is an important 
therapeutic goal in the management of people with schizophrenia7.  
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Although previous studies have identified clinical indicators of poor outcome in general, there 
have been relatively few studies investigating risk factors for treatment-resistance specifically. 
The research that has been undertaken indicates that an early age of onset of psychosis, male 
sex, a longer duration of untreated psychosis, and poor premorbid functioning may be 
associated with treatment-resistance8-10. Although one study reported an enrichment of 
schizophrenia PRS in clozapine-treated patients10, this has not been replicated in larger 
subsequent studies11,12. Other studies have reported an increased burden of genome-wide rare 
copy number duplications in treatment-resistant patients12, and an excess of rare disruptive 
variants in gene targets of antipsychotics13, although both of these studies are yet to be 
independently replicated. The identification of reliable factors could serve to alert clinicians and 
help predict those at greater risk of developing treatment-resistance when they first present 
with psychosis. This study aims to gain insights and identify factors measurable at illness onset 
that could be used predict treatment-resistant psychosis (TRP).  
Methods 
Sample characteristics 
Study individuals were from the CardiffCOGS (COGnition in Schizophrenia, n=1070) sample, 
which has been previously described14,15 and additional details are provided in Supplementary 
Methods. CardiffCOGS is a sample of patients with clinically diagnosed schizophrenia or related 
psychotic disorders recruited from community, in-patient and voluntary sector mental health 
services in the UK. Study individuals completed a comprehensive clinical interview based on the 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) instrument, donated a blood 
sample for genetic analysis, and consented for access to their clinical case notes. The SCAN 
interview and clinical case notes were used to arrive at DSM-IV and ICD-10 lifetime diagnoses 
and to complete OPCRIT ratings. All study individuals had a diagnosis of schizophrenia or related 
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psychotic disorder (detailed in Supplementary Table 1). We included individuals with related 
psychotic disorders in addition to those with schizophrenia given that the study focuses on 
prediction at first presentation and diagnosis can be uncertain at this time. Thus, we refer to all 
samples as either TRP or non-TRP (whether the diagnosis is schizophrenia or a related psychotic 
disorder) and we undertake sensitivity analyses for all results to examine whether effects are 
consistent when restricted to those with narrowly defined schizophrenia. The sample shows a 
degree of enrichment for TRP as a result of targeted recruitment from clozapine clinics (52.4% 
compared to a TRP prevalence of ~30%). The study had multi-site NHS ethics approval granted 
by South East Wales Research Ethics Committee Panel (REC reference number: 07/WSE03/110) 
and written informed consent was obtained for all study participants. 
Outcome variable 
Study individuals were diagnosed with TRP if they had either been rated negatively for OPCRIT 
item 89 ‘psychotic symptoms respond to neuroleptics’ or had received clozapine treatment. 
Individuals were diagnosed with non-TRP if they were rated positively for OPCRIT item 89 and 
had not received clozapine. OPCRIT item 89 was rated globally over the total period of illness 
based on interview and clinical notes data and scored positively if the illness appeared to 
respond to any type of antipsychotic or if relapse occurred when medication was stopped. 
Individuals were excluded from the analyses (n=82) if (i) despite failure to respond to 
antipsychotics, they had not yet received two adequate antipsychotic trials at time of data 
collection or (ii) there was insufficient information to determine antipsychotic response. 
Demographic, premorbid and illness onset clinical factors  
To investigate characteristics that could at illness onset prospectively indicate a higher risk of 
TRP, we investigated variables related to demographics and family background, premorbid 
factors, and characteristics related to illness onset. These variables were derived from self-
 6 
report at interview, clinical case notes and OPCRIT ratings. Full definitions of these variables are 
given in Supplementary Table 2. The demographic factors assessed included; (i) sex, (ii) 
urbanicity, (iii) family history of schizophrenia, (iv) family history of a psychotic disorder, 
affective disorder or suicide, (v) mother’s age at birth, and (vi) father’s age at birth. The 
premorbid factors investigated included; (i) birth complications, (ii) complications during their 
mother’s pregnancy, (iii) developmental problems, (iv) childhood abuse, (v) total years spent in 
education, (vi) highest level of education, (vii) premorbid IQ, (viii) poor premorbid social 
adjustment, and (ix) poor premorbid work adjustment. Features related to the first illness 
presentation included; (i) age of onset of psychosis, (ii) duration of untreated psychosis, (iii) 
regular cannabis use in the year prior to illness onset, (iv) regular cigarette smoking in the year 
prior to illness onset, (v) a psychosocial stressor in the six months prior to onset of psychosis, 
and (vi) the mode of onset of psychosis.  
Lifetime characteristics 
In a secondary analysis, we investigated differences in post-onset symptom and outcome 
measures between individuals with TRP and non-TRP. These variables included demographics, 
lifetime clinical characteristics, clinical symptoms, and substance use (full details in 
Supplementary Table 3). 
Genetic liability for schizophrenia 
Genotyping and quality control 
The CardiffCOGS sample was genotyped on either the Illumina HumanOmniExpressExome-8 or 
the Illumina HumanOmniExpress-12 array as previously described15. After standard QC 
procedures, imputation was performed using IMPUTE216 and the 1000 Genomes (phase 3) and 
UK10K reference panels17. Genetic analyses were restricted to those of European ancestry, 
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assessed by principal component analysis, and related individuals with 𝜋𝜋 > 0.2 were identified 
and one member removed at random. Complete details of genotyping and quality control of the 
CardiffCOGS sample are provided in a prior publication15 and Supplementary Methods. 
Schizophrenia polygenic risk score (PRS) 
PRS were created based on the largest published schizophrenia GWAS meta-analysis15, 
excluding individuals from CardiffCOGS. Scores were calculated following the method described 
by Wray et al18 (Supplementary Methods). We selected nine p-value thresholds (5 x 10-8, 1 x 10-
6, 1 x 10-4, 0.001, 0.01, 0.05, 0.1, 0.2, 0.5) to compute PRS scores.  
Copy number variation (CNVs) 
The identification and quality control of CNVs in the CardiffCOGS sample has been previously 
described19 and detailed in Supplementary Methods. To compare the enrichment of rare, 
pathogenic CNVs in TRP with non-TRP, we analysed the presence of an intellectual disability 
associated (ID) CNV20, the presence of a CNV previously associated with schizophrenia19, and the 
presence of any chromosomal deletions and duplications spanning 500kb or 1Mb in length.  
Analysis 
We conducted descriptive analyses to compare lifetime illness-related symptoms and outcome 
measures across TRP and non-TRP cases via univariate logistic regression. To assess the 
association of clinical predictive factors with TRP, we conducted univariate logistic regressions 
for each variable adjusting for age at interview and method of recruitment (defined as 
recruitment from secondary mental health care services such as clinician referral or clozapine 
clinic, or from other sources such as opportunistic or via third sector organisations). To control 
for multiple testing of 21 variables, we applied a Bonferroni correction threshold of p ≤ 2.38x10-
3.  
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Multivariate prediction modelling of TRP consisted of two approaches (i) multivariate logistic 
regression including variables associated at p < 0.1 from univariate analyses and covarying for 
age at interview and recruitment method, and (ii) conditional inference random forests model. 
Machine learning ensemble methods, such as the conditional inference random forests model, 
have been shown to have superior performance in detecting independent associations with 
health outcomes in comparison to logistic regression21. The conditional inference random forest 
model was implemented via the ‘cforest’ function in the R ‘party’ package22, which is 
recommended for models that have variables of different types and that are correlated 
(Supplementary Figure 1)23. The model was fitted based on 4000 trees (selected via grid search) 
and an unbiased variable selection to control for different variable types. To derive an 
importance value for each variable, conditional permutation was used to control for any 
correlated variables. This permuted importance value represents the decrease in classification 
accuracy after randomly permuting the values of that variable over all trees. The accuracy of the 
conditional inference forest model was derived using the R ‘caret’ package24. The primary forest 
model could only be conducted in individuals with no missing data for the 21 variables analysed 
(n=337), and so we repeated the analyses in the remaining sample (up to n=733) for the five 
variables with the highest importance from the primary analysis. In order to make a direct 
comparison between the logistic regression and conditional inference forest models, we 
conducted a multivariate logistic regression in the 337 individuals with complete data. Rates of 
missing data for each variable are detailed in Supplementary Table 2. The differences between 
individuals with and without missing data was assessed via logistic regression and detailed in 
Supplementary Table 4; there was no difference in sex, age at interview or method of 
recruitment but the participants with no missing data were less likely to have TRP (OR = 0.65, 
95% CI = 0.50-0.84, p = 0.001).  
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To test the relationship between common variant genetic liability for schizophrenia on TRP, we 
regressed a model for each polygenic risk score created from various training p-value thresholds 
against a base model including the first five principal components and any additional principal 
components from the first 20 that were associated (p < 0.05) with TRP. To assess the proportion 
of variance explained we computed R2 on the liability scale25, based on a TRP lifetime 
prevalence of 30% in schizophrenia, to account for ascertainment bias. The association of CNVs 
with TRP was tested via Firth’s logistic regression26.  
As this sample includes those with schizophrenia and related psychotic disorders, all analyses 
were replicated restricting the sample to those with a schizophrenia or schizoaffective disorder, 
depressed type diagnosis. 
 
Results 
A total 561 (52.4%) of the individuals included in the study were diagnosed with TRP and 509 
(47.6%) with non-TRP. Due to our sampling methodology for this genetic study the vast majority 
of the participants (96.9%) were of White European ethnicity, and a total of 662 (61.9%) were 
male. Study individuals with TRP had a younger age at interview compared to those with non-
TRP (OR = 0.98, 95% CI = 0.97-0.99, p = 6.48x10-4) and were more likely to have been recruited 
from secondary mental care services (OR = 2.32, 95% CI = 1.76-3.04, p = 1.52 x10-9). As potential 
confounders of no experimental interest both of these factors were included as covariates in 
subsequent regression analyses. 
Lifetime characteristics  
In a descriptive comparison of post-onset symptom and outcome measures, we found that 
individuals with TRP were more severely impaired than those with non-TRP across a range of 
 10 
measures (Supplementary Table 5). Individuals with TRP were significantly more likely to have a 
continuous course of disorder, poorer cognitive functioning at the time of the interview, a 
higher number of psychiatric inpatient admissions, a lower GAS score, to have deteriorated from 
their premorbid level of functioning, to have been detained under the Mental Health Act, and to 
have a schizophrenia diagnosis. Furthermore, study individuals with TRP had more severe 
lifetime positive and negative symptoms. The strengths of the associations were equivalent in 
analyses restricted to individuals with schizophrenia or schizoaffective depression 
(Supplementary Table 6).  
Demographic, premorbid and illness onset clinical factors  
Univariate logistic regression 
The association of demographic, premorbid and illness onset clinical factors with TRP are listed 
in Table 1. Univariate analyses in the total sample (up to n=1070) found significant associations 
with TRP for an earlier age of onset of psychosis (OR = 0.94, 95% CI = 0.92-0.96, p = 7.79x10-13) 
and poor premorbid social adjustment (OR = 1.64, 95% CI = 1.26-2.13, p = 2.41x10-4). Lower 
premorbid IQ, poor premorbid work adjustment, and cannabis use in the year prior to illness 
onset were associated with TRP at p < 0.05 but did not survive correction for multiple testing.  
Multivariate logistic regression 
Clinical factors associated at p < 0.1 with TRP from the univariate analysis were included in a 
multivariate logistic regression (Table 1, n=621). We found that an earlier age of onset of 
psychosis (OR = 0.95, 95% CI = 0.92-0.97, p = 1.60-5), poor premorbid social adjustment (OR = 
1.88, 95% CI = 1.27-2.78, p = 1.49x10-3), lower premorbid IQ (OR = 0.98, 95% CI = 0.96-0.99, p = 
7.76x10-3), younger father’s age at birth (OR = 0.97, 95% CI = 0.95-0.99, p = 0.015), and cannabis 
use in the year prior to onset of psychosis (OR = 1.60, 95% CI = 1.06-2.41, p = 0.025) predicted 
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TRP. The multivariate model explained 16.3% of the variance (Nagelkerke R2 of multivariate 
model minus that explained by covariates alone) of TRP. These associations remained consistent 
in regression analyses restricting the sample to individuals with schizophrenia and 
schizoaffective depression (Supplementary Table 7).  
Conditional inference forest model 
A conditional inference forest model was fitted to predict TRP based on 4000 trees using all 21 
clinical factors previously described for 337 individuals with no missing data. The accuracy of the 
predictive model in this training dataset was 0.59. Using conditional permutation for importance 
factors (which represents the decrease in classification accuracy if the values of that variable are 
randomly permuted), we found that a younger age of onset of psychosis was the most 
important factor in the prediction of TRP, followed by poor premorbid social adjustment, family 
history of schizophrenia, lower premorbid IQ and poor premorbid work adjustment (Figure 1). 
These findings were consistent in a model restricted to individuals with a diagnosis of 
schizophrenia (Supplementary Figure 2). The importance of these top five variables was 
replicated in 428 individuals that were excluded from the primary forest model analysis on the 
basis of having one or more of the 21 clinical factors missing. Age of onset of psychosis was 
again the most important factor for TRP prediction, followed by premorbid IQ and poor 
premorbid social adjustment. A logistic regression model for the 337 individuals included in the 
primary model is provided in Supplementary Table 8 for a direct comparison between the 
methods, although the findings from this restricted set are consistent with the primary 
regression analysis in any case. 
[ Figure 1 approximately here ] 
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Genetic liability for schizophrenia  
Schizophrenia polygenic risk score (PRS) 
Although individuals with TRP had a higher schizophrenia PRS on average across the p-value 
thresholds from the discovery cohort, this difference was only associated at a single threshold of 
P < 0.001 (Table 2; R2 = 0.011, OR = 1.20, 95% CI = 1.03-1.39, p = 0.016). These findings were 
consistent in analyses restricted to those with schizophrenia or schizoaffective depression 
(Supplementary Table 9). This study had 80% power to detect an association at p < 0.05, if the 
correlation between genetic effects on schizophrenia and TRP was 49% 27.  
Copy number variation (CNVs) 
We found that there was no difference in the burden of rare, pathogenic CNVs previously 
associated with schizophrenia or intellectual disability in individuals with TRP compared to those 
with non-TRP (Table 2). Furthermore, we found no enrichment of 500kb or 1Mb deletions or 
duplications in individuals with TRP. These findings were consistent in analyses restricted to 
those with schizophrenia or schizoaffective depression (Supplementary Table 10). Our sample 
size had 80% power to detect an OR > 1.7 for a burden of CNVs with a frequency of 2.5% 28 at a 
significance level of p < 0.05 29. 
As genetic liability for schizophrenia (CNVs or PRS) was not associated with TRP, they were not 
combined in multivariate analyses with clinical factors. 
Post hoc analyses related to age of onset of psychosis 
Given the significant association of age of onset of psychosis with TRP, we conducted additional 
exploratory analyses. The association between TRP and age of onset of psychosis was consistent 
for males (OR = 0.95, 95% CI = 0.93-0.97, p = 3x10-6) and females (OR = 0.93, 95% CI = 0.90-0.95, 
p = 7.9x10-8). To investigate whether clozapine-prescribing practice could be influencing these 
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results, we restricted the analysis to TRP patients that had not received clozapine treatment 
(n=87) and found the association between age of onset of psychosis and TRP remained (OR = 
0.95, 95% CI = 0.92-0.98, p = 5.88 x 10-4).  
Age of onset of psychosis alone explained 7.3% of the variance (Nagelkerke R2) of TRP, and had 
an area under the curve of 0.65. Figure 2 displays the relationship between age of onset and the 
proportion with TRP in our sample (data used given in Supplementary Table 11). Assuming a 
TRP prevalence of 30%, we found that the positive predictive value for non-TRP was 0.51 for 
those with an age of onset less than 16, and this increased to 0.60, 0.66, 0.73, 0.79, and 0.92 for 
ages of onset between 16-20, 21-25, 26-30, 31-40 and 41 years and over respectively 
(Supplementary Table 12). 
We investigated whether the relationship between age of onset of psychosis and TRP could be 
explained by genetic liability to schizophrenia indicated by PRS and found that schizophrenia 
PRS was associated with the age of onset of psychosis (Supplementary Tables 13-14; at SNP 
threshold p < 0.01: R2 = 0.006, Beta = -0.86, 95% CI = -1.62--0.10, p = 0.027). The association 
between age of onset of psychosis and TRP (OR = 0.94, 95% CI = 0.92-0.96, p = 4.60x10-11) was 
not attenuated when conditioning on schizophrenia PRS (OR = 0.94, 95% CI = 0.92-0.96, p = 
6.38x10-11). 
[ Figure 2 approximately here ] 
Discussion 
In this study we used regression and machine-learning analyses to determine whether genetic 
liability for schizophrenia and/or clinical characteristics measurable at illness onset can 
prospectively indicate a higher risk of TRP. We found age of onset of psychosis to be a significant 
and important clinical indicator in TRP. In addition, we found evidence across models that poor 
premorbid social functioning and lower premorbid IQ increased the risk of TRP. Genetic liability 
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for schizophrenia indicated by polygenic risk scores and rare, pathogenic CNVs were not 
associated with TRP and did not explain the relationship with age of onset of psychosis.  
Main findings 
Age of onset of psychosis, defined as the age at which treatment was first sought or when 
symptoms first caused significant impairment (if earlier), was the most important indicator of 
TRP in this study; it was significant in univariate and multivariate regression analyses (OR = 0.95, 
95% CI = 0.92-0.97) and had the highest importance value from conditional inference forest 
model. These findings were consistent in analyses restricting the sample to individuals with a 
schizophrenia diagnosis and were not influenced by clozapine-prescribing practice. An early age 
of onset of psychosis has been previously identified in several pervious studies as a predictor of 
TRP8,9,12. This study provides evidence that the increased risk for TRP is not restricted to those 
with a very early onset as suggested by previous studies30,31 but rather the risk of TRP continued 
to reduce throughout adulthood; the positive predictive value for treatment response to 
standard antipsychotics increased from 0.51 for individuals with an age of onset below 16 to 
0.92 for those with an age of onset over 41 years of age. Given the continued reduction in the 
risk of TRP throughout adulthood, it seems unlikely that the relationship is explained by 
differences in provision of health services or related factors across different age groups. 
Nonetheless, these findings do suggest the importance of engagement and proactive 
management of patients with an early age of onset of psychosis. 
In this study we also found evidence for the role of premorbid factors in TRP. Poor premorbid 
social functioning, defined as a difficulty entering or maintaining social relationships, isolation or 
social withdrawal prior to the onset of psychotic symptoms, was significantly associated with 
TRP in univariate and multiple regression analyses (OR = 1.88, 95% CI = 1.27-2.78) and rated as 
important in the conditional inference forest model. This finding is consistent with previous 
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studies, which have identified premorbid social functioning as predictive of poor outcomes in 
schizophrenia and also TRP32. Furthermore, lower premorbid IQ (estimated from the National 
Adult Reading Test) was associated with an increased risk of TRP in multivariate regression 
analysis (OR = 0.98, 95% CI = 0.96-0.99) and was identified by the conditional inference forest 
model as predictive. These premorbid factors have been implicated in other studies of poor 
outcomes in schizophrenia10,33, and warrant further investigation for their role in treatment-
resistance. The association of premorbid factors with TRP suggests that the 
neurodevelopmental hypothesis of schizophrenia may have relevance to treatment outcomes 
and warrants further investigation. The multivariate logistic regression also found some 
evidence for the role of father’s age at birth, and cannabis use in the year prior to onset of 
psychosis in TRP. However, these factors were not identified in the forest model and thus 
replication is required to investigate their role in TRP.  
In this study we did not find evidence of an association between TRP and several established risk 
factors for schizophrenia such as male sex, childhood abuse, duration of untreated psychosis, 
family history of psychosis, or urbanicity. A lack of association with these variables has also been 
reported in other studies of TRP8,12, and provides support against a psychosis spectrum theory, 
under which you would expect to find increased rates of risk factors for schizophrenia in TRP. 
However, in the case of early adversity, a previous study reported a cumulative effect of lifetime 
adversity in TRP34, suggesting that although we did not find an independent association with 
childhood abuse, it is possible it could be contributing to TRP in a cumulative manner.  
We found no evidence for the association of genetic liability for schizophrenia indicated by PRS 
or rare, pathogenic CNVs with TRP. These findings are consistent with other studies 
investigating the association of schizophrenia PRS with TRP10-12, suggesting that genetic liability 
to TRP is not strongly influenced by liability to schizophrenia, beyond of course the requirement 
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to have schizophrenia. However, larger samples are required to provide definitive answers in 
this regard. Within the power limitations of the study design, our findings add support to other 
evidence3 suggesting that treatment-resistance may not be best conceptualised as a form of 
illness at the severe end of a psychosis spectrum, in which case you would expect a higher 
genetic loading of generic schizophrenia-associated SNPs in TRP patients. The use of PRS in the 
personalised prediction of TRP may be better informed by more specific training sets, for 
example from genetic studies investigating TRP directly, as opposed to PRS derived from those 
with a broad schizophrenia diagnosis.  
Schizophrenia PRS was weakly associated with age of onset of psychosis in this study. However, 
the relationship between TRP and age of onset of psychosis in this study was not confounded or 
explained by differences in genetic liability to schizophrenia, suggesting that genetic factors 
influencing the age of onset of psychosis are distinct from those that increase liability for the 
disorder and may have particular relevance to treatment-resistance.  
Lifetime characteristics 
In a descriptive comparison of post-onset symptom and outcome measures, we found that 
individuals with TRP were more severely impaired than those with non-TRP; they were 
significantly more likely to have a continuous course of disorder, poorer cognitive functioning at 
the time of the interview, a higher number of psychiatric inpatient admissions, a lower GAS 
score, were more likely to deteriorate from their premorbid level of functioning, more likely to 
have been detained under the Mental Health Act, and have more severe positive and negative 
symptoms. Many of these findings have been previously documented2, but few studies have 
looked at so many variables in a single cohort of this size. These findings reinforce the 
importance of efforts to identify early indicators of TRP and thus improve the ability of clinicians 
to identify and appropriately treat those with an increased risk of TRP.  
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Strengths and limitations 
A strength of the study is the use of a single large schizophrenia and related psychotic disorders 
sample with detailed clinical phenotypes derived from both interview and clinical case notes. 
Consequently, the outcome variable of TRP is of a high quality, including confirmed treatment-
responders as controls, which is not the case for many studies in this field. We did not have 
objective evidence (such as medication serum levels) to confirm treatment resistance but our 
TRP definition takes non-adherence into account given it relies upon either clinician diagnosis of 
treatment resistance to prescribe clozapine or was based on ratings from interview and clinical 
note review taking into account reported non-adherence. A further strength is the use of both 
regression and machine learning approaches. Machine learning models are increasingly being 
applied in prediction models for disease and to inform the personalised prevention of disease35.  
The primary limitation of this study is the use of retrospective reports for the premorbid and 
illness onset variables although the use of contemporaneous clinical records will have increased 
the reliability of the key clinical variables such as age of onset of psychosis. The study sample is 
enriched for individuals with TRP (52% vs. estimated 30% prevalence) as a result of targeted 
recruitment from clozapine clinics. Recruitment strategy was controlled for in regression 
analyses, which did not alter the results, and all predictive values were corrected for prevalence 
and thus we do not believe that this enrichment biases the results of the study. We found minor 
but consistent levels of missing data across clinical variables, which significantly reduced the 
sample size in multivariate analyses. However, we were able to replicate our findings in these 
excluded individuals for smaller subsets of associated variables. We were not able to 
incorporate some factors into the present study that may have impacted the likelihood of 
treatment-resistance such as type of individual antipsychotics prescribed and other treatments 
received. Lastly, like many genetic studies, our analyses primarily consisted of individuals of 
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White European ethnicity and thus further studies are required to establish the generalisability 
of these findings to all TRP patients. 
Future research and clinical implications 
The results in this study indicate that genetic studies investigating TRP directly, rather than a 
broad schizophrenia diagnosis, will be needed to gain insights into the nature of treatment-
resistance in schizophrenia and related psychotic disorders. Age of onset of psychosis, poor 
premorbid social functioning and premorbid IQ may serve as useful indicators, along with other 
factors, in a predictive algorithm for TRP. From a clinical perspective, the results indicate that 
patients with these characteristics are less likely to respond to standard antipsychotic 
treatment, and thus require additional monitoring, support, and perhaps clozapine treatment 
should be considered earlier. Measures of genetic liability to schizophrenia were not associated 
with TRP in this sample, indicating that the genetic architecture of susceptibility to 
schizophrenia may be distinct from that of treatment outcomes. 
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Table 1: Demographic, premorbid and illness onset predictors of TRP  
 
TRP 
 
Non-TRP 
 
Adjusted Univariate (up to N=1070)  Fully Adjusted Multivariate (N=621) 
 
N (%) / mean (sd) Total N 
 
N (%) / mean (sd) Total N 
 
OR (95% CI) P  OR (95% CI) P 
Demographics and family background 
        
   
Male sex 361 (64.3%) 561 
 
300 (59.1%) 508 
 
1.24 (0.97-1.60) 0.092  1.03 (0.71-1.49) 0.899 
Urbanicity (city birth and upbringing) 184 (41.5%) 443 
 
175 (38.8%) 451 
 
1.23 (0.94-1.63) 0.137    
Family Hx of schizophrenia 126 (26.2%) 481 
 
92 (20.8%) 442 
 
1.37 (1.00-1.88) 0.051  1.03 (0.68-1.57) 0.877 
Family Hx of psychosis, affective or suicide 255 (54.6%) 467 
 
253 (57.1%) 443 
 
0.86 (0.67-1.13) 0.276    
Mother’s age at birth 26.71 (sd=6.3) 490 
 
27.16 (sd=6.1) 475 
 
0.99 (0.97-1.01) 0.466    
Father’s age at birth 29.38 (sd=7.3) 469 
 
30.22 (sd=7.3) 447 
 
0.98 (0.97-1.00) 0.096  0.97 (0.95-0.99) 0.015 
Premorbid factors 
        
   
Birth complications 113 (23.8%) 475 
 
102 (22.5%) 453 
 
1.09 (0.79-1.49) 0.604    
Pregnancy complications 48 (10.4%) 461 
 
40 (9.3%) 432 
 
1.18 (0.75-1.86) 0.477    
Developmental problems 100 (20.4%) 491 
 
73 (15.9%) 460 
 
1.32 (0.94-1.86) 0.109    
Childhood abuse 102 (20.1%) 508 
 
93 (19.5%) 467 
 
1.08 (0.78-1.49) 0.650    
Years in education 12.75 (sd=3.5) 536 
 
13.22 (sd=2.9) 494 
 
0.95 (0.91-1.00) 0.032  0.98 (0.93-1.04) 0.557 
Highest level of education 2.59 (sd=1.7) 539 
 
2.88 (sd=1.8) 501 
 
0.92 (0.85-0.99) 0.019  1.11 (0.96-1.28) 0.163 
Premorbid IQ (NART) 97.05 (sd=13.5) 516 
 
100.4 (sd=12.9) 437 
 
0.99 (0.98-1.00) 3.59x10-3  0.98 (0.96-0.99) 7.76x10-3 
Poor premorbid social adjustment 238 (44.7%) 532 
 
163 (33.7%) 484 
 
1.64 (1.26-2.13) 2.41x10-4  1.88 (1.27-2.78) 1.49x10-3 
Poor premorbid work adjustment 114 (22.1%) 515 
 
71 (14.8%) 481 
 
1.60 (1.15-2.23) 5.48x10-3  1.33 (0.81-2.17) 0.261 
Illness presentation 
        
   
Definite psychosocial stressor within 6 m 40 (7.6%) 524 
 
54 (11.2%) 483 
 
0.67 (0.43-1.04) 0.077  0.79 (0.41-1.50) 0.465 
Age of onset of psychosis 23.00 (sd=8.0) 540 
 
27.83 (sd=10.2) 487 
 
0.94 (0.92-0.96) 7.97x10-13  0.95 (0.92-0.97) 1.60x10-5 
Duration of untreated psychosis (years) 2.14 (sd=4.6) 522 
 
1.98 (sd=4.22) 474 
 
1.02 (0.99-1.05) 0.290    
Cannabis use in year prior to onset 186 (36.1%) 515 
 
121 (25.3%) 479 
 
1.53 (1.14-2.06) 5.13x10-3  1.60 (1.06-2.41) 0.025 
Cigarette smoking prior to onset 303 (65.6%) 462 
 
285 (62.0%) 460 
 
1.18 (0.90-1.56) 0.240    
Insidious disease onset (1-6) 3.64 (sd=1.4) 433 
 
3.49 (sd=1.4) 428 
 
1.05 (0.95-1.15) 0.377    
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Table 1: Association of demographic, premorbid and illness onset clinical factors with 
treatment-resistant schizophrenia (TRP). Columns represent clinical variables, TRP, non-TRP 
(reference group), odds ratio (OR), 95% confidence intervals (CI) and P-value from univariate 
logistic regression adjusted for age at interview and method of recruitment, and adjusted 
multivariate logistic regression. For binary variables, numbers (N) and percentages (%) are 
provided, and for continuous variables, mean and standard deviation (sd) are provided. P-values 
in bold were significant at P < 0.05. 
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Table 2: Association of genetic liability for schizophrenia with TRP 
Schizophrenia polygenic risk score  
Score P-value Threshold OR (95% CI) R2 AUC SE P-value  
P < 1 x 10-8 1.06 (0.92-1.21) 0.0011 0.515 0.0025 0.428 
P < 1 x 10-6 1.05 (0.91-1.20) 0.0007 0.513 0.0021 0.520 
P < 1 x 10-4 1.08 (0.94-1.24) 0.0021 0.521 0.0035 0.296 
P < 1 x 10-3 1.20 (1.03-1.39) 0.0110 0.549 0.0081 0.016 
P < 0.01 1.11 (0.94-1.30) 0.0030 0.526 0.0043 0.212 
P < 0.05 1.09 (0.92-1.31) 0.0020 0.521 0.0035 0.319 
P < 0.1 1.07 (0.89-1.28) 0.0011 0.517 0.0026 0.469 
P < 0.2 1.13 (0.94-1.37) 0.0032 0.526 0.0044 0.204 
P < 0.5 1.08 (0.89-1.31) 0.0013 0.517 0.0028 0.441 
Copy number variation 
 
TRP N (%) 
Total = 429 
Non-TRP N (%) 
Total = 411 OR (95% CI) P 
Intellectual disability pathogenic CNV 9 (2.1%) 11 (2.7%) 0.79 (0.32-1.88) 0.588 
Schizophrenia pathogenic CNV 7 (1.6%) 11 (2.7%) 0.62 (0.23-1.55) 0.305 
>500kb deletion 12 (2.8%) 10 (2.4%) 1.14 (0.50-2.69) 0.750 
>1Mb deletion 5 (1.2%) 1 (0.2%) 3.55 (0.70-34.68) 0.131 
>500kb duplication 34 (7.9%) 31 (7.5%) 1.05 (0.64-1.75) 0.838 
>1Mb duplication 8 (1.9%) 14 (3.4%) 0.55 (0.22-1.28) 0.168 
Table 2: Association of genetic liability for schizophrenia with TRP. Columns for schizophrenia 
PRS represent the p-value threshold used in discovery cohort to derive scores, odds ratio (OR) 
and 95% confidence intervals, R2 calculated on the liability scale25 , area under the curve (AUC), 
standard error (SE), and P-value of association of each score of with TRP. Columns for CNV 
analysis represent CNVs assessed, frequencies of each CNV in non-TRP (reference group), TRP, 
odds ratio (OR), 95% confidence intervals (CI) and P-value from Firth’s logistic regression. 
 26 
Figure 1: Variable importance from conditional inference forests model 
 
Figure 1: Variable importance plots from conditional inference forests models predicting TRP. 
Plot A: Permuted importance from primary analysis (n=337 with complete data for all 21 
variables assessed). Plot B: Permuted importance from replication analysis for top five variables 
in remaining sample (n=428). 
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Figure 2: Proportions of individuals with TRP by age of onset of psychosis 
 
 
Figure 2: Quadratic fit plot of proportion of sample that have treatment-resistant schizophrenia 
(TRP). Green dots represent proportion of sample with TRP for each age of onset. Grey area 
represents 95% confidence intervals. Data used to produce plot is provided in Supplementary 
Table 11; the minimum number of per group was 23 individuals, and the mean average number 
per group was 40 individuals.  
 
